Shirsand S B, Suresh Sarasija, Para M S, Swamy P V
Department of Pharmaceutical Technology, H. K. E. Society's College of Pharmacy, Sedam Road, Gulbarga-585 105, India.
Indian J Pharm Sci. 2009 Jul;71(4):447-51. doi: 10.4103/0250-474X.57298.
In the present work, fast disintegrating tablets of prochlorperazine maleate were designed with a view to enhance patient compliance by effervescent method. In this method, mixtures of sodium bicarbonate and anhydrous citric acid in different ratios along with crospovidone (2-10% w/w), croscarmellose sodium (2-10% w/w) were used as superdisintegrants. Estimation of prochlorperazine maleate in the prepared tablet formulations was carried out by extracting the drug with methanol and measuring the absorbance at 254.5 nm. The prepared formulations were further evaluated for hardness, friability, drug content uniformity and in vitro dispersion time. Based on in vitro dispersion time (approximately 13-21 s), two promising formulations (one from each super-disintegrant) were tested for in vitro drug release pattern in pH 6.8 phosphate buffer, short-term stability (at 40 degrees /75% relative humidity for 3 mo) and drug-excipient interaction (IR spectroscopy). Among the two promising formulations, the formulation containing 10% w/w of crospovidone and mixture of 20% w/w sodium bicarbonate and 15% w/w of citric acid emerged as the overall best formulation (t(50%) 6 min) based on drug release characteristics in pH 6.8 phosphate buffer compared to commercial conventional tablet formulation (t(50%) 17.4 min). Short-term stability studies on the promising formulations indicated that there are no significant changes in drug content and in vitro dispersion time (p<0.05).
在本研究中,设计了马来酸氯丙嗪速崩片,旨在通过泡腾法提高患者的顺应性。在该方法中,使用不同比例的碳酸氢钠和无水柠檬酸混合物以及交联聚维酮(2-10% w/w)、交联羧甲基纤维素钠(2-10% w/w)作为超级崩解剂。通过用甲醇提取药物并在254.5 nm处测量吸光度,对制备的片剂制剂中的马来酸氯丙嗪进行含量测定。对制备的制剂进一步进行硬度、脆碎度、药物含量均匀度和体外分散时间的评估。基于体外分散时间(约13-21秒),对两种有前景的制剂(每种超级崩解剂各一种)在pH 6.8磷酸盐缓冲液中进行体外药物释放模式测试、短期稳定性(在40℃/75%相对湿度下放置3个月)以及药物-辅料相互作用(红外光谱)测试。在这两种有前景的制剂中,含有10% w/w交联聚维酮以及20% w/w碳酸氢钠和15% w/w柠檬酸混合物的制剂,基于在pH 6.8磷酸盐缓冲液中的药物释放特性,与市售传统片剂制剂(t(50%) 17.4分钟)相比,成为总体最佳制剂(t(50%) 6分钟)。对有前景的制剂进行的短期稳定性研究表明,药物含量和体外分散时间没有显著变化(p<0.05)。